The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development and clinical dosage manufacturing, preclinical pharmacology and toxicology, and a reagent program for HIV and other infectious diseases. The period of performance is from October 15, 2020 through October 14, 2027.
One initial task order was awarded against the contract to the American Type Culture Collection, doing business as Atcc, for $10,735,150.98 to maintain the Reagent Program for HIV and other infectious diseases through identification, acquisition, production, receipt, storage, maintenance, distribution and disposal of biological and chemical research organisms, materials and associated products to support preclinical research efforts in Manassas, Virginia through January 2024. The purpose of the contract and initial task order is to provide resources and services to support the development of therapies, vaccines and diagnostics for HIV, hepatitis B and C, tuberculosis, and other infectious diseases through preclinical research studies.
Generated 1/4/24, 9:31 PM